BioCentury
ARTICLE | Clinical News

Trimesta: Completed Phase II enrollment

March 19, 2012 7:00 AM UTC

Synthetic Biologics (formerly Adeona Pharmaceuticals Inc.) completed enrollment of 164 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 8 mg Trimesta daily plus Copaxon...